Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01090128 · ClinicalTrials.gov registry record · Phase 1
Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer
A Phase 1 study, sponsored by University of Utah.
- Terminated
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT01090128 is a Phase 1 study that was terminated before completion, run by University of Utah. The registered enrollment target is 27 participants.
The verdict
NCT01090128, a Phase 1 study, was terminated before completion, sponsored by University of Utah.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to test whether treatment of patients with breast cancer with the combination of Abraxane (nab-paclitaxel), Adriamycin (doxorubicin), and Cyclophosphamide prior to surgery is safe and results in good tumor response. Up to 24 patients may be enrolled in this study at the Mitchell Cancer Institute. All patients enrolling in this study will receive treatment with the combination of Abraxane, Adriamycin, and Cyclophosphamide.
Interventions
- DRUG cyclophosphamide
- DRUG doxorubicin
- DRUG Nanoparticle Albumin Bound Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2008-09 |
| Est. Completion | 2017-03-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01090128
The ClinicalTrials.gov registry entry for NCT01090128 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which cyclophosphamide is the first listed.
NCT01090128 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01090128 about?
NCT01090128 is a clinical study titled "Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer". The purpose of this clinical trial is to test whether treatment of patients with breast cancer with the combination of Abraxane (nab-paclitaxel), Adriamycin (doxorubicin), and Cyclophosphamide prior to surgery is safe and results in good tumor response. Up to 24 patients may be enrolled in this stud...
What is the current status of trial NCT01090128?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2008-09. Estimated completion is 2017-03-24.
What interventions are being tested in trial NCT01090128?
The interventions under investigation include: cyclophosphamide (DRUG), doxorubicin (DRUG), Nanoparticle Albumin Bound Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT01090128?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.